Deutsche Bank AG Raises Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Deutsche Bank AG boosted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 40.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 147,020 shares of the biopharmaceutical company's stock after buying an additional 42,272 shares during the quarter. Deutsche Bank AG owned approximately 0.09% of TG Therapeutics worth $4,425,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quadrant Capital Group LLC raised its holdings in TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after acquiring an additional 975 shares during the last quarter. Blue Trust Inc. raised its holdings in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after acquiring an additional 1,737 shares during the last quarter. Finally, Synergy Asset Management LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at about $75,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Trading Up 1.0%

Shares of NASDAQ TGTX traded up $0.33 during midday trading on Friday, reaching $34.57. 1,042,767 shares of the stock were exchanged, compared to its average volume of 2,989,933. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock has a market capitalization of $5.49 billion, a P/E ratio of -345.67 and a beta of 2.21. The company has a 50 day simple moving average of $38.13 and a 200 day simple moving average of $34.32. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The company had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business's revenue for the quarter was up 90.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.07) EPS. As a group, equities analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Wall Street Zen upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.